Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Life sciences tools company Esco Lifesciences Group has scored $200m in a series A and crossover round co-led by Novo Holdings and Vivo Capital. Funds will be used to expand the company's presence ...

After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic ...